Eli Lilly's orforglipron demonstrates significant advantages over Novo Nordisk's Rybelsus, achieving superior weight loss and better A1C reduction in recent trials. As Eli Lilly showcases strong sales of $14.7 billion in the first half of 2025 and continues to expand its portfolio, Novo Nordisk grapples with a 28.1% share decline and a revised outlook. The competition intensifies in the lucrative GLP-1 market, compounded by high-stakes developments such as Novo's cardiovascular approval for Rybelsus.
“GLP-1 market · has been in the spotlight for · the past couple of years · multi-billion-dollar potential”
“Novo Nordisk · currently dominates · GLP-1 market · true”
“Eli Lilly · currently dominates · GLP-1 market · true”
“Eli Lilly · reported · ACHIEVE-3 head-to-head study data · orforglipron outperformed Rybelsus”
“Novo Nordisk · responded with data from · REACH real-world head-to-head study · true”
“NVO’s Ozempic · reduced the risk of MACE · 23% compared with LLY’s Trulicity · true”
“Ozempic · remains the only GLP-1 RA approved to lower · risk of kidney disease progression and cardiovascular death · true”
“Novo Nordisk · secured · EU approval to add cardiovascular benefits to Rybelsus · true”
“Mounjaro and Zepbound · have become · LLY’s key top-line drivers · true”
“Eli Lilly · generated combined sales of · $14.7 billion in the first half of 2025 · true”
“LKTX · is developing · VK2735 · as an oral and subcutaneous formulations for obesity”
“Novo Nordisk’s shares · have lost · 28.1% · year to date”
